Keros Therapeutics Inc (KROS)
$11.03
$-0.05
(-0.45%)
As on 14-Sep-2026 10:32EDT
Market cap
$220 Mln
Revenue (TTM)
$33 Mln
P/E Ratio
--
P/B Ratio
0.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-13
-
Debt to Equity
0
-
Book Value
$13.2
-
EPS
$-3.7
-
Face value
--
-
Shares outstanding
19,827,188
6 Years Aggregate
CFO
$-302.57 Mln
EBITDA
$-384.83 Mln
Net Profit
$-375.46 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Keros Therapeutics Inc (KROS)
| -45.8 | 3.5 | 8.7 | -29.6 | -32.2 | -18.6 | -- |
|
BSE Sensex*
| -11.7 | -4.8 | 1.1 | -8.2 | 3.9 | 5.1 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Keros Therapeutics Inc (KROS)
| 28.6 | -59.9 | -17.2 | -17.9 | -17.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Keros Therapeutics Inc (KROS)
|
11.0 | 219.7 | 33.2 | -83.2 | -259.5 | -29.4 | -- | 0.8 |
| 81.6 | 11,702.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 25.1 | |
| 73.6 | 10,255.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.2 | 13,905.5 | 2,435.9 | 860.6 | 31.0 | 43 | 17.6 | 7.5 | |
| 107.1 | 12,167.0 | 1,663.7 | 413.6 | 36.3 | 430 | 31.4 | 84.6 | |
| 344.6 | 10,270.8 | 440.5 | 241.5 | 33.4 | 18.7 | 43.3 | 7.6 | |
| 532.1 | 12,348.9 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.5 | |
| 591.6 | 16,398.7 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.5 | 37.5 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 | |
| 330.6 | 9,341.5 | 0.0 | -339.1 | -- | -30.6 | -- | 7.0 |
Shareholding Pattern
View DetailsAbout Keros Therapeutics Inc (KROS)
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the... United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Read more
-
President, CEO, Treasurer, & Director
Dr. Jasbir S. Seehra Ph.D.
-
President, CEO, Treasurer, & Director
Dr. Jasbir S. Seehra Ph.D.
-
Headquarters
Lexington, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Keros Therapeutics Inc (KROS)
What is the current share price of Keros Therapeutics Inc (KROS) Today?
The share price of Keros Therapeutics Inc (KROS) is $11.03 (NASDAQ) as of 14-Sep-2026 10:32 EDT. Keros Therapeutics Inc (KROS) has given a return of -32.17% in the last 3 years.
What is the current PB & PE ratio of Keros Therapeutics Inc (KROS)?
Since, TTM earnings of Keros Therapeutics Inc (KROS) is negative, P/E ratio is not available.
The P/B ratio of Keros Therapeutics Inc (KROS) is 0.85 times as on 11-Sep-2026, a 83 discount to its peers’ median range of 4.92 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
6.36 |
1.83 |
2024 |
-3.41 |
1.12 |
2023 |
-7.83 |
3.61 |
2022 |
-12.54 |
4.73 |
2021 |
-23.34 |
5.64 |
What is the 52 Week High and Low of Keros Therapeutics Inc (KROS)?
The 52-week high and low of Keros Therapeutics Inc (KROS) are Rs 22.55 and Rs 9.69 as of 14-Sep-2026.
What is the market cap of Keros Therapeutics Inc (KROS)?
Keros Therapeutics Inc (KROS) has a market capitalisation of $ 220 Mln as on 11-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Keros Therapeutics Inc (KROS)?
Before investing in Keros Therapeutics Inc (KROS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.